Seeking Alpha

Pozen (POZN) says the U.S. Court of Appeals has upheld the Texas District Court's ruling that...

Pozen (POZN) says the U.S. Court of Appeals has upheld the Texas District Court's ruling that had originally found in favor of POZN against several generic pharmaceutical companies which had filed Abbreviated New Drug Applications seeking FDA approval to market generic copies of Treximet. Treximet is marketed by POZN's exclusive U.S. licensee, GlaxoSmithKline (GSK).
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector